Treatment of Latent Tuberculosis Infection

Publication Date: February 14, 2020
Last Updated: March 14, 2022

Recommendations for regimens to treat latent tuberculosis infection

Having trouble viewing table?
Priority rank* Regimen Recommendation
(strong or conditional)
(high, moderate, low, or very low)
Preferred 3 mos isoniazid plus rifapentine given once weekly Strong Moderate
Preferred 4 mos rifampin given daily Strong Moderate (HIV negative)
Preferred 3 mos isoniazid plus rifampin given daily Conditional Very low (HIV negative)
Conditional Low (HIV positive)
Alternative 6 mos isoniazid given daily Strong§ Moderate (HIV negative)
Conditional Moderate (HIV positive)
Alternative 9 mos isoniazid given daily Conditional Moderate
* Preferred: excellent tolerability and efficacy, shorter treatment duration, higher completion rates than longer regimens and therefore higher effectiveness; alternative: excellent efficacy but concerns regarding longer treatment duration, lower completion rates, and therefore lower effectiveness.
No evidence reported in HIV-positive persons.
§ Strong recommendation for those persons unable to take a preferred regimen (e.g., due to drug intolerability or drug-drug interactions).

Recommendation Grading



Treatment of Latent Tuberculosis Infection

Authoring Organization

Publication Month/Year

February 14, 2020

Last Updated Month/Year

February 5, 2024

Document Type


External Publication Status


Country of Publication


Inclusion Criteria

Female, Male, Adolescent, Adult, Child, Infant, Older adult

Health Care Settings

Emergency care, Hospital

Intended Users

Epidemiology infection prevention, nurse, nurse practitioner, physician, physician assistant


Management, Treatment

Diseases/Conditions (MeSH)

D014376 - Tuberculosis


tuberculosis, Mycobacterium tuberculosis, latent tuberculosis infection, Tuberculosis

Source Citation

Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020;69(No. RR-1):1–11. DOI:

Supplemental Methodology Resources

Data Supplement